

### **Remarks**

Claims 1-6, 9-12, and 14-17 are pending in this Application. Claims 1-6, 9-12, and 14-17 are subject to an election requirement.

In the present Preliminary Amendment, claims 6 and 11 have been amended to correct an inadvertent typographical error in the spelling of “temozolomide.” The correct spelling of “temolozomide” can be found on page 24, line 23 of the specification as originally filed. “Temozolomide” is the generic name for the drug TEMODAR<sup>TM</sup> (see the sentence on page 24, line 23 bridging page 25, line 1). TEMODAR<sup>TM</sup> is used in the experiments described in Examples 1-2 of the specification as originally filed, which can be found on page 29, line 30 through page 31, line 22.

Therefore, Applicant submits that no new matter is added by these amendments.

Please charge any fees that may be required for the processing of this Response, or credit any overpayments, to our Deposit Account Number 03-1721. Applicant would like to thank the Examiner in advance for review of this request.

Respectfully submitted,

Dated October 17, 2007

/BHJarrell/  
Brenda Herschbach Jarrell, Ph.D.  
Reg. No.: 39,223

CHOATE, HALL & STEWART LLP  
Patent Group  
Two International Place  
Boston, MA 02110  
Tel: 617-248-5000  
Fax: 617-248-4000